Mark Leschly

Managing Partner, Rho Ventures

Mark is Managing Partner of Rho Capital Partners and Rho Ventures and serves on the investment committee of Rho Fund Investors. He has spent over thirteen years in the venture capital and private equity business. Prior to joining Rho in 1999, he spent five years at Healthcare Ventures where he was a general partner. Previously, he had several years of management consulting experience at McKinsey & Company. Mark received an MBA from Stanford Graduate School of Business. His current and former board involvement includes: Anacor, Archemix, BroadLogic, Gloucester, Inotek, Memory Pharmaceuticals, MPV, NitroMed, Orametrix, Orqis, Ripe Digital Entertainment, Senomyx, SiTV, Slacker, Tercica, TolerRx, Vanda Pharmaceuticals, Verenium (formerly Diversa), and Vicuron.